• Join SITC
  • Renew
Make a Gift
Skip to main content (Press Enter).
Sign in
Skip auxiliary navigation (Press Enter).
  • Subscribe
Society for Immunotherapy of Cancer (SITC) logo. This will take you to the homepage
Society for Immunotherapy of Cancer (SITC) logo. This will take you to the homepage
Skip main navigation (Press Enter).
  • Educational & Scientific Programs
      • ConnectED
      • Advances in Cancer Immunotherapy™
      • Collaborative Education Programs
      • 2023 Spring Scientific
      • Workshops
      • Tumor Immune Microenvironment: A Holistic Approach
      • Surfaceome Virtual Workshop
      • Bispecific T cell Engagers Virtual Workshop
      • Cytokines in Cancer Immunotherapy Virtual Workshop
      • Call for Proposals
      • Annual Meeting & Pre-Conference Programs
      • 37th Annual Meeting & Pre-Conference Programs
      • Past and Future Annual Meetings & Pre-Conference Programs
      • Cancer Immunotherapy Winter School
      • Patient and Survivor Education and Resources
      • Webinars and Online Education
      • ACI Online Interactive Courses
      • Advances in Cancer Immunotherapy (ACI) Webinars
      • Meet-the-Expert Webinars
      • SITC Clinical Practice Guidelines Online Education
      • SITC-NCI Computational IO Series
      • Targets for Cancer IO: A Deep Dive Series
      • Calendar of Events
  • Professional Development & Training
      • Certificate in Cancer Immunotherapy
      • Meet-the-Expert Program
      • Meet-the-Expert Webinars
      • NCI Immunotherapy Fellowship
      • SITC Sparkathon
      • SITC Sparkathon 2.0 Accelerator
      • Support Sparkathon
      • Other Resources
      • Calendar of Events
      • Path to SITC Leadership
      • Clinical Trials Training and Resources
      • SITC Clinical Immuno-Oncology Network (SCION) Workshop
      • Maximizing the Value of Phase III Trials in Immuno-Oncology
      • Professional Interest Communities
      • Fellowships
      • Women in Cancer Immunotherapy Network (WIN)
      • Women in Cancer Immunotherapy Network 2022
      • Women in SITC Community
      • Early Career Scientist (ECS) Committee
  • Publications & Guidelines
      • Journal for ImmunoTherapy of Cancer
      • About JITC
      • Become a Reviewer
      • For Authors
      • From the Editors
      • JITC Collections and Special Issues
      • SITC Immunotherapy Books
      • SITC's Guide to Managing Immunotherapy Toxicity Textbook
      • Cancer Immunotherapy Principles and Practice Textbook, 2nd Ed.
      • SITC Clinical Practice Guidelines
      • Clinical Practice Guidelines
      • Clinical Practice Guidelines Online Education
      • Clinical Practice Guidelines Mobile App
      • Patient Resource Guides
  • Policy & Advocacy
      • Advocacy
      • Crisis in Clinical Research
      • Global Immunotherapy Access
      • Government Relations
      • Quality and Value
      • Patient & Survivor Education & Resources
  • Membership
      • Academy of Immuno-Oncology
      • About the Academy
      • Nomination and Selection
      • Members Only
      • SITC Member Directory
      • Renew Your Membership
      • Become a SITC Member
      • Membership Benefits
      • Submit an Application
      • Membership Categories
      • Volunteer
      • Volunteer with SITC
      • Connect-a-Colleague
      • Corporate Membership
      • Path to SITC Leadership
  • Support SITC
      • The Forward Fund
      • Moving the Field Forward
      • Making a Difference
      • Named Funds and Awards
      • Early Career Scientist Awards
      • Richard V. Smalley Memorial Award and Lectureship
      • Steven A. Rosenberg Scholars Award
      • Technology Awards
      • Martin "Mac" Cheever Travel Award Fund
      • Sparkathon 2.0 Accelerator
      • The CheckPoints: SITC’s House Band
      • Ways to Make a Gift
      • Donate
      • Stocks and Securities
      • Estate and Planned Gifts
      • Corporate Support and Giving Opportunities
      • Corporate Giving Opportunities
      • Corporate Membership
      • Educational Grants
      • Sponsorship & Advertising
      • SITC Merchandise
      • Honor and Memorial Gifts
      • Make a Gift in Honor of a Loved One
      • Make a Gift in Memory of a Loved One
      • Our Donors and Supporters
      • 2022 SITC Supporters
      • Forward Fund Donors
  • About SITC
      • Awards and Recognition
      • Committees, Task Forces and Professional Interest Communities
      • Partnerships
      • SITC Policies
      • Board of Directors
      • Elevating a Rich Oncology Community: SITC’s DEI Strategic Plan
      • Media Room
      • SITC Press Releases
      • Scientific Meeting Highlights from SITC
      • Immune Monitor Archive
      • JITC Digest Archive
      • Cancer Immunotherapy Month
      • Career Connections
      • Mission & Vision
      • Contact SITC
      • SITC Staff
      • Contact Us
  • The Connect Community
      • Create Account
      • My Profile
      • My Communities
      • My Libraries
      • The Sentinel - SITC Blog

SITC 29th Annual Meeting

The SITC 2014 Annual Meeting Presentation Archive is supported through a generous contribution from Prometheus Laboratories Inc.

Access slide decks and video via the links in the schedule below.

PDF = click on presentation title to view .pdf version of slides.

VIDEO = presentation video is available. Click on the icon to view video. (Note: if no .pdf version is available for a given presentation, video will be linked from the presentation title.)

Friday, November 7, 2014

7:15 am – 8:00 am Meet-the-Expert Breakfast (Early Career Scientist Event)
0 AMA PRA Category 1 Credits™ (not CME-certified)
7:15 am – 8:00 am Meet-the-Expert Breakfast (Early Career Scientist Event)
0 AMA PRA Category 1 Credits™ (not CME-certified)
 8:00 am – 8:35 am Presidential Welcome and Update Session
.5 AMA PRA Category 1 Credits™
8:00 am – 8:05 am Presidential Welcome  PDF  VIDEO
Francesco M. Marincola, MD – Sidra Medical and Research Center
8:05 am – 8:20 am Update Session: U.S. Food and Drug Administration  PDF
Raj K. Puri, MD, PhD – U.S. Food and Drug Administration
8:20 am – 8:35 am Update Session: National Cancer Institute  PDF
William D. Merritt, PhD – National Cancer Institute
8:35 am – 9:25 am Richard V. Smalley, MD Memorial Lectureship: Cancer as a Disease of the Metaorganism
.75 AMA PRA Category 1 Credits™
8:35 am – 8:40 am Introduction  VIDEO
Francesco M. Marincola, MD – Sidra Medical and Research Center
8:40 am – 9:25 am Cancer as a Disease of the Metaorganism  PDF
Giorgio Trinchieri, MD – National Cancer Institute
9:25 am – 12:00 pm Inflammation, Innate Immunity and Microbiome
2.25 AMA PRA Category 1 Credits
Co-Chairs:
Marco Colonna, MD – Washington University
William J. Murphy, PhD – University of California-Davis
9:25 am – 9:30 am Session Overview  VIDEO
William J. Murphy, PhD – University of California-Davis
 9:30 am – 9:55 am Natural Killer Cell Subsets in Immune Regulation and Tumor Immunity  PDF  VIDEO
William J. Murphy, PhD – University of California-Davis
9:55 am – 10:20 am Natural Killer Cells and Innate Lymphoid Cells in Inflammation and Cancer  PDF  VIDEO
Marco Colonna, MD – Washington University
10:20 am – 10:40 am Break
10:40 am – 10:55 am Direct Activation of STING in the Tumor Microenvironment with Synthetic Cyclic Dinucleotide Derivatives Leads to Potent and Systemic Tumor-Specific Immunity
Leticia Corrales, PhD – University of Chicago
10:55 am – 11:10 am Evidence Implicating the Commensal Microbiota in Shaping Anti-Tumor Immunity in Melanoma
Ayelet Sivan – University of Chicago
11:10 am – 11:35 am The Role of the Intestinal Microbiome on GVHD  PDF
Marcel R.M. van den Brink, MD, PhD – Memorial Sloan-Kettering
Cancer Center
11:35 am – 12:00 pm Roles of the Microbiota in Immunity and Inflammation
Yasmine Belkaid, PhD – National Institutes of Health
12:00 pm – 12:30 pm Late-Breaking Abstract Session
0 AMA PRA Category 1 Credits™ (not CME-certified)
12:00 pm – 12:15 pm TCR Repertoire Divergence Reflects Microenvironmental Immune Phenotypes in Glioma  PDF
Jennifer Sims, PhD – Columbia University
12:15 pm – 12:30 pm Activation of Toll-Like Receptor-2 by Tumor Associated Matrix Metalloproteinase-2 Modulates Dendritic Cell Function
Nina Bhardwaj, MD PhD – Icahn School of Medicine at Mt. Sinai
12:30 pm – 2:00 pm Lunch, Poster Viewing and Exhibits
Oral Poster Session 12:50 pm – 1:40 pm
2:00 pm – 4:15 pm Lung Cancer: Immunology and Immunotherapy
2.25 AMA PRA Category 1 Credits™
Co-Chairs:
Roy S. Herbst, MD, PhD – Yale Cancer Center
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
2:00 pm – 2:05 pm Session Overview
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
2:05 pm – 2:30 pm Personalizing Lung Cancer Immunotherapy
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy
2:30 pm – 2:55 pm Personalized Immunotherapy for Non-Small Cell Lung Cancer  PDF  VIDEO
Roy S. Herbst, MD, PhD – Yale Cancer Center
2:55 pm – 3:10 pm TG4010 Immunotherapy Combined with First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study  PDF  VIDEO
John Nemunaitis, MD – Mary Crowley Medical Research Center
3:10 pm – 3:25 pm PD-L1 Expression Correlates with Immune Response in a Phase I Trial of CCL21 Gene Modified Dendritic Cell Therapy in Lung Cancer
Jay M. Lee, MD – University of California, Los Angeles
3:25 pm – 3:50 pm Manipulating Tumor-Immune Cell Interactions in NSCLC
Mikael J. Pittet, PhD – Mass General Hospital
3:50 pm – 4:15 pm PD-1 Immune Checkpoint Blockade: Patient Characteristics and Biomarkers Associated with Response  PDF  VIDEO
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4:15 pm – 4:45 pm Break
4:45 pm – 6:10 pm Concurrent Session — Tumor Microenvironment and Immunosuppression
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County
Weiping Zou, MD, PhD – University of Michigan
4:45 pm – 4:50 pm Session Overview
Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County
4:50 pm – 5:10 pm Neutralizing Immune Suppression in the Tumor Microenvironment
Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County
5:10 pm – 5:35 pm Integrating Immunoregulatory and Vascular Signaling Programs Through Lectin-Glycan Interactions  PDF
Gabriel A. Rabinovich, PhD – Instituto de Biología y Medicina Experimental (IBYME)
5:35 pm – 5:55 pm Immune Impact on Cancer Stemness  PDF  VIDEO
Weiping Zou, MD, PhD – University of Michigan
5:55 pm – 6:10 pm FcgRIIIA (CD16)-Expressing Monocytes Mediate the Depletion of Tumor-Infiltrating Tregs Via Ipilimumab-Dependent ADCC in Melanoma Patients  PDF
Emanuela Romano, MD, PhD – University Hospital of Lausanne
4:45 pm – 6:10 pm Concurrent Session — Immunopotentiation by Radiotherapy: Mechanisms and Opportunities
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Sandra Demaria, MD – New York University
Susan Knox, MD, PhD – Stanford University
4:45 pm – 4:50 pm Session Overview  VIDEO
Susan Knox, MD, PhD – Stanford University
4:50 pm – 5:15 pm New Directions with NKT Cells and Nanoscale Flow Cytometry
Jennifer Clare Jones, MD, PhD – National Cancer Institute
5:15 pm – 5:40 pm Radiotherapy with TGF-β Blockade Jump-Starts Tumor-Specific T Cells and Immune Checkpoint Inhibitors Keep Them Going  PDF  VIDEO
Sandra Demaria, MD – New York University
5:40 pm – 5:55 pm The Anti-Tumor Immune Response Generated by Radiation Therapy May be Limited by Tumor Cell Adaptive Resistance and can be Circumvented by PD-L1 Blockade  PDF  VIDEO
Simon Dovedi, PhD, MSc, BSC – University of Manchester
5:55 pm – 6:10 pm CD47 Limits Cooperation between Adaptive Tumor Immunity and Radiation Therapy  PDF  VIDEO
David D. Roberts, PhD – National Cancer Institute

Saturday, November 8, 2014

8:00 am – 8:35 am Welcome and Update Session
.5 AMA PRA Category 1 Credits™
8:00 am – 8:05 am Welcome and Overview  VIDEO
Kim A. Margolin, MD – Stanford University
8:05 am – 8:10 am Update Session: SITC Biomarkers Task Force  PDF  VIDEO
Lisa H. Butterfield, PhD – University of Pittsburgh
8:10 am – 8:35 am Update Session: Cancer Immunotherapy Trials Network
Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center
8:35 am – 9:25 am Keynote Address: Prophylactic Cancer Vaccines - Feasibility and Progress
.75 AMA PRA Category 1 Credits™
Olivera J. Finn, PhD – University of Pittsburgh
9:25 am – 12:00 pm Barriers to Successful Vaccines
2.25 AMA PRA Category 1 Credits™
Co-Chairs:
Jonathan L. Bramson, PhD – McMaster University
Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne
9:25 am – 9:45 am Session Overview  VIDEO
Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne
9:45 am – 10:05 am Immunotherapy and the Immunosuppressive Tumor Network
Gosse J. Adema, PhD – Radboud University Medical Center
10:05 am – 10:25 am Antigen-Specific T Cell Responses to Breast Cancer  PDF
Jill E. Slansky, PhD – University of Colorado
10:25 am – 10:45 am Break
10:45 am – 11:00 am Functional Redundancy of PI3K Isoforms in Conventional T Cells Provides a Selective Treg-Targeting Strategy Through Inhibition of PI3K-Delta Isoform
Shamim Ahmad, PhD – Georgia Regents University Cancer Center
11:00 am – 11:15 am Vaccine Targeting HIF1A in Triple Negative Breast Cancer  PDF  VIDEO
Mary L. Disis, MD, FACP – University of Washington
11:15 am – 11:35 am Local, Regional, and Systemic Effects of TLR Agonists and IFA as Adjuvants for Peptide Vaccines  PDF
Craig L. Slingluff, Jr., MD – University of Virginia
11:35 am – 11:55 am The Use of Peptides in the Therapeutic Vaccination of Cancer  PDF  VIDEO
Hans-Georg Rammensee, PhD – Universitäet Tüebingen
11:55 am – 12:00 pm Closing Remarks   VIDEO
Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne
12:00 pm – 12:30 pm Late-Breaking Abstract Session
0 AMA PRA Category 1 Credits™ (not CME-certified)
12:00 pm – 12:15 pm DNA Vaccine VGX-3100 with Electroporation Induces Regression of Cervical Intraepithelial Neoplasia 2/3 and Clears HPV Infection with Robust T Cell Responses: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial  PDF
Laurent M. Humeau, PhD – Inovio Pharmaceuticals
12:15 pm – 12:30 pm OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells with a Unique T Cell Receptor Repertoire and Synergizes with PDL1 Blockade to Promote Tumor Regression  PDF
Amy E. Moran, PhD – Earle A. Chiles Cancer Research Institute, Providence Cancer Center
12:30 pm – 2:00 pm Lunch, Poster Viewing and Exhibits
O
ral Poster Session 12:50 pm – 1:50 pm
2:00 pm – 3:05 pm Presidential Session
1.0 AMA PRA Category 1 Credits™
2:00 pm – 2:05 pm Introduction  VIDEO
Francesco M. Marincola, MD – Sidra Medical and Research Center
2:05 pm – 2:20 pm Tumor Derived Stress Triggers C/EBPβ Homologous Protein (CHOP) Expression in Myeloid Derived Suppressor Cells (MDSC) and Mediates Immunosuppressive Activity  PDF
Paul Thevenot, PhD – Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center
2:20 pm – 2:35 pm Mechanisms of TIGIT-Driven Immune Suppression in Cancer
Sema Kurtulus, PhD – Center for Neurologic Diseases Brigham &
Women’s Hospital
2:35 pm – 2:50 pm Melanoma-Intrinsic B-Catenin Signaling Prevents T Cell Infiltration and Anti-Tumor Immunity
Stefani Spranger, PhD – University of Chicago
2:50 pm – 3:05 pm Pre-Clinical Validation of a Humanized Anti-EGFR Variant III Chimeric Antigen Receptor and Phase I Trial of CART-EGFRvIII in Glioblastoma
Marcela Maus, MD, PhD – University of Pennsylvania
3:05 pm – 3:25 pm Immunoscore Update  PDF  VIDEO
.25 AMA PRA Category 1 Credits™
Bernard A. Fox, PhD – Earle A. Chiles Cancer Research Institute,
Providence Cancer Center
3:25 pm – 4:00 pm Break
4:00 pm – 5:25 pm Concurrent Session — Coinhibition and Costimulation: Targets and Strategies
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute,
Providence Cancer Center
Robert H. Vonderheide, MD, DPhil – University of Pennsylvania
4:00 pm – 4:05 pm Session Overview  VIDEO
Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute,
Providence Cancer Center
4:05 pm – 4:30 pm OX40 Immunotherapy in Cancer Patients: Immunological Observations and Implications for T Cell Immunotherapy  PDF  VIDEO
Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence
Cancer Center
4:30 pm – 4:45 pm Distinct Immunologic Changes In Vivo Following Combination Versus Individual PD-1 or CTLA-4 Checkpoint Blockade in Human Cancer
Kavita Dhodapkar, MD – Yale University
4:45 pm – 5:00 pm Melanoma Progression is Associated with NK Cell Exhaustion
Ines Pires da Silva, MD – New York University Cancer Center
5:00 pm – 5:25 pm CD40 Agonists in Cancer Immunotherapy  PDF  VIDEO
Robert H. Vonderheide, MD, DPhil – University of Pennsylvania
4:00 pm – 5:25 pm Concurrent Session — High Throughput Technologies: Determinants of the Immune Response to Cancer
1.5 AMA PRA Category 1 Credits™
Co-Chairs:
Katherine L. Nathanson, MD – University of Pennsylvania
Paul F. Robbins, PhD – National Institutes of Health/National Cancer Institute
4:00 pm – 4:05 pm Session Overview  PDF  VIDEO
Katherine L. Nathanson, MD – University of Pennsylvania
4:05 pm – 4:30 pm Use of High Throughput Sequencing to Identify Mutated Tumor Antigens  PDF  VIDEO
Paul F. Robbins, PhD – National Institutes of Health/National Cancer Institute
4:30 pm – 4:50 pm Inherited Genetic Response
Kevin M. Brown, PhD – National Cancer Institute
4:50 pm – 5:10 pm Single Cell Functional Analysis Provides Insights into Cancer Patient Responses, including the Development of Resistance, to Cell-Based and Combination Immunotherapies  PDF  VIDEO
James R. Heath, PhD – California Institute of Technology
5:10 pm – 5:25 pm T Cell Receptor Diversity Evaluation to Predict Patient Response to Ipilimumab in Metastatic Melanoma  PDF  VIDEO
Michael Postow, MD – Memorial Sloan-Kettering Cancer Center

Sunday, November 9, 2014

8:00 am – 10:15 am Adoptive Immunotherapy
2.25 AMA PRA Category 1 Credits™
Co-Chairs:
Helen E. Heslop, MD – Baylor College of Medicine
Per thor Straten, PhD – Centre for Cancer Immune Therapy (CCIT)
8:00 am – 8:05 am Session Overview  VIDEO
Helen E. Heslop, MD – Baylor College of Medicine
8:05 am – 8:30 am Moving Tumor Infiltrating Lymphocytes and Biomarkers Forward  PDF  VIDEO
Patrick Hwu, MD – University of Texas, MD Anderson Cancer Center
8:30 am – 8:55 am Melanoma Therapy using Adoptive Transfer of Expanded Tumor Infiltrating T cells; Prospects and Pitfalls  PDF  VIDEO
Per thor Straten, PhD – Centre for Cancer Immune Therapy (CCIT)
8:55 am – 9:10 am Toward Cell Transfer Immunotherapy Against Patient-Specific Mutations in Gastrointestinal Cancers  PDF
Eric Tran, PhD – National Insitutes of Health/National Cancer
Institute
9:10 am – 9:25 am Modulating Immunometabolism of Tumor Specific CD8 T Cells to Enhance T Cell Based Therapy for Cancer  PDF  VIDEO
Madhusudhanan Sukumar, PhD – National Cancer Institute
9:25 am – 9:50 am Enhancing the IQ of CAR T Cells  PDF  VIDEO
Michael C.V. Jensen, MD – University of Washington
9:50 am – 10:15 am CAR Therapy: The CD19 Paradigm
Michel Sadelain, MD, PhD – Memorial Sloan-Kettering Cancer Center
10:15 am Annual Meeting Adjourns

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




Membership Links

Join

Renew

Member Directory

My Profile

Get Involved

Email Sign-up

Volunteer

Support SITC

Contact Us

© 2023 Society for Immunotherapy of Cancer (SITC). All rights reserved.
555 East Wells Street, Suite 1100 | Milwaukee, WI | 53202-3823 | USA

Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: info@sitcancer.org

Powered by Higher Logic